摘要
Abstract
Objective To evaluate the changes of interleukin-1,2,6(IL-1,2,6),insulinlike growth factor Ⅱ(IGF Ⅱ)and bone mineral density(BMD)in patients with low bone mass or postmenopausal osteoporosis(PMO).Methods The serum levels of IL-1,2,6 and IGFⅡ in 80 cases of osteoporosis or low bone mass postmenopausal women accompanied by bone-ache(double-positive group),40 cases of normal bone mass postmentopausal women without boneache(double-negative group)and 30 cases of healthy young women(young group)were determined with a sensitive radioimmunoassay by BMD of calcaneus were measured by SXA.The double-positive group were further divided into 2 treating groups:premarin group(n=40),premarin combined with etidronate disodium tablets(HEBP) group(n=40).After one year of treament,the serum levels of IL-1,2,6 and IGF Ⅱ in patients of 2 treating groups were redetermined.BMD in postmenopausal women of double-positive group and douple-negative group was measured every 6 months for 2 times.Results ①The serum levels of IL-1,2,6 and IGF Ⅱ in all postmenopausal women had an increasing trend.②After treatment,the serum levels of IL-2,6 and IGF Ⅱ in patients of premarin combined with HEBP group decreased significantly as compared with those before treatment(P＜0.01,＜0.01,＜0.05).There were no statistical difference among serum levels of IL-1,2,6 and IGF Ⅱ in premarin group as compared with those before treatment(P＞0.05,respectively).③Premarin could delay bone loss,but couldn't increase bone mass.Combined therapy not only delay bone loss but also increase bone mass.④The bone loss rates of 6th month and 12th month in double-negative group were 1.21% and 2.86%,respectively.Conclusion In postmenopausal women,IL-1,2,6 and IGF Ⅱ are overproduced and they may involve in immunal damage of skeletal system.Measuring IL-1,2,6 and IGFⅡ levels may have important value in judging bone loss and guiding therapy of PMO.The 2 treating methods have some therapeutic effects on PMO.Combined therapy appears to work better.关键词
绝经后骨质疏松/胰岛素样生长因子Ⅱ/白细胞介素1,2,6/依屈磷酸二钠分类
医药卫生
